In the past week, Leap Therapeutics Inc (NASDAQ:LPTX) has garnered considerable attention from investors and the situation remained the same on Thursday as the stock clocked gains of as much as 36%. That took its gains for the past week to as much as 70%.
In light of such considerable gains, it might be a good idea for investors to take a closer look at the announcement made by Leap Therapeutics yesterday. The company announced that it had been presented with positive data from the Phase 2a clinical trial which is looking into the possibility of using DKN-01 for treating cancer.
The product in question is a anti-Dickkopf-1 antibody and remains one of the more ambitious projects at Leap Therapeutics at this point in time. In addition to that, it is also necessary to note that on September 17, 2021, the company is going to host a conference call with regards to the latest findings with regards to this product.
Hence, it is likely that the Leap Therapeutics stock is going to come into focus among investors today depending on the comments from the company at the conference call later on.
